Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Consolidated Net Income: 2012-2024

Historic Consolidated Net Income for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to -$409.2 million.

  • Ascendis Pharma A's Consolidated Net Income rose 41.10% to -$62.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$236.4 million, marking a year-over-year increase of 47.15%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
  • Per Ascendis Pharma A's latest filing, its Consolidated Net Income stood at -$409.2 million for FY2024, which was up 21.00% from -$518.0 million recorded in FY2023.
  • Ascendis Pharma A's 5-year Consolidated Net Income high stood at -$409.2 million for FY2024, and its period low was -$595.0 million during FY2022.
  • For the 3-year period, Ascendis Pharma A's Consolidated Net Income averaged around -$507.4 million, with its median value being -$518.0 million (2023).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first slumped by 219,311.36% in 2020, then increased by 21.00% in 2024.
  • Yearly analysis of 5 years shows Ascendis Pharma A's Consolidated Net Income stood at -$478.4 million in 2020, then climbed by 8.27% to -$438.8 million in 2021, then slumped by 35.60% to -$595.0 million in 2022, then rose by 12.94% to -$518.0 million in 2023, then rose by 21.00% to -$409.2 million in 2024.